Eli Lilly Looks To Positive Data To Expand Its Market Opportunity For Emgality [Seeking Alpha]
ALDER BIOPHARMACEUTICALS INC (ALDR)
Last alder biopharmaceuticals inc earnings: 8/6 04:07 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.alderbio.com/node/5806
Company Research
Source: Seeking Alpha
Eli Lilly Looks To Positive Data To Expand Its Market Opportunity For Emgality Summary Eli Lilly announced that it had achieved a positive outcome in its phase 3 study in that the primary endpoint was met with statistical significance. It was shown that Emgality was able to reduce monthly migraine headache days by about 4.1 days, compared to placebo with only 1.0 day. Sales for Emgality in Q2 of 2019 reached $33.8 million. Competition is fierce in the CGRP space with several other companies in place like Amgen and Novartis, Teva, and soon to possibly be Alder BioPharmaceuticals. LLY Phase 3 Data Provides Solid New Option For Patients The phase 3 trial was known as CONQUER. This late-stage study recruited patients with chronic and episodic migraines. Emgality was given to these patients to act as a preventative treatment for them. However, one thing to note is that this was a population of patients who had failed on two or four prior standard-of-care (SOC) treatments. Why would these p
Show less
Read more
Impact Snapshot
Event Time:
ALDR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALDR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALDR alerts
High impacting ALDER BIOPHARMACEUTICALS INC news events
Weekly update
A roundup of the hottest topics